Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Decrease in Short Interest

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totalling 226,400 shares, a decline of 93.3% from the July 15th total of 3,380,000 shares. Based on an average trading volume of 12,390,000 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Kazia Therapeutics in a report on Friday, July 12th.

Institutional Trading of Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. Armistice Capital LLC purchased a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,475,555 shares of the company’s stock, valued at approximately $1,088,000. Armistice Capital LLC owned 15.15% of Kazia Therapeutics at the end of the most recent reporting period. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Stock Performance

Shares of KZIA traded down $0.02 during midday trading on Monday, hitting $0.41. The stock had a trading volume of 658,443 shares, compared to its average volume of 5,627,450. The company has a 50 day simple moving average of $0.36 and a two-hundred day simple moving average of $0.32. Kazia Therapeutics has a twelve month low of $0.19 and a twelve month high of $1.58.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.